Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results. Those who would like to participate may access the live webc...
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference - Rapidly transforming into a leading global biopharma company COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update on Monday, January 12, during the 44th Annual J.P. Morgan Healthcare Conference. “With our proven TransCon® technology platform, strong R&D capabilities, an...
We believe that in addition to a strong safety profile, ASND's combo should demonstrate better efficacy on both linear growth and body proportionality (Fig. 2 & Fig. 3).Figure 1 - Combination Therapy Improves and Maintains Mean AGV to Above the 97th Percential of Average-Stature ChildrenSource:
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) – Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy – Combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, alignin...
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference and provide a business update on Monday, January 12, 2026, at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time in San Francisco, California. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at . A webcast replay will also be available on this...
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia – Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) notified the Company that information submitted on November 5, 2025, related to the post-marketing requirement, in response to the FDA’s ongoing review of the New Drug Application (NDA) for TransCon CNP (navepegritide) for ch...
Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational once-weekly TransCon® CNP (navepegritide) in children with achondroplasia have been published in JAMA Pediatrics, a journal of the American Medical Association. In the publication, titled “Once-Weekly Navepegritide in Children with Achondroplasi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.